Last reviewed · How we verify
Follitropin Epsilon
Follitropin Epsilon is a recombinant human follicle-stimulating hormone used to stimulate follicular growth in the ovaries.
Follitropin Epsilon is a recombinant human follicle-stimulating hormone used to stimulate follicular growth in the ovaries. Used for Induction of ovulation in women with polycystic ovary syndrome (PCOS) who do not ovulate, Assisted reproduction in women with diminished ovarian reserve.
At a glance
| Generic name | Follitropin Epsilon |
|---|---|
| Also known as | FSH-GEX(TM) |
| Sponsor | Glycotope GmbH |
| Drug class | Gonadotropin |
| Target | FSH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Health |
| Phase | Phase 2 |
Mechanism of action
It works by mimicking the action of the natural hormone follicle-stimulating hormone, which is essential for the growth and maturation of ovarian follicles. This leads to an increase in estrogen levels and the development of multiple follicles, making it a potential treatment for infertility and other conditions related to ovulation.
Approved indications
- Induction of ovulation in women with polycystic ovary syndrome (PCOS) who do not ovulate
- Assisted reproduction in women with diminished ovarian reserve
Common side effects
- Ovarian hyperstimulation syndrome
- Multiple pregnancy
- Headache
- Nausea
- Injection site reaction
Key clinical trials
- Single Dose FSH-GEX™ in Healthy Volunteers (PHASE1)
- Multiple Dose FSH-GEX(TM) in Healthy Volunteers (PHASE1)
- Efficacy and Safety of FSH-GEX™ in Comparison With 150 IU Gonal-f® (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Follitropin Epsilon CI brief — competitive landscape report
- Follitropin Epsilon updates RSS · CI watch RSS
- Glycotope GmbH portfolio CI